Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 24, 2025, titled "Dr. Reddy s receives European Commission approval for AVT03 (denosumab), a proposed Biosimilar of Prolia® and Xgeva®".
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts more than Nifty 100 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's Laboratories has received approval from the European Commission for AVT03 (denosumab), a proposed biosimilar of Prolia® and Xgeva®. Prolia and Xgeva are widely used biologic drugs (developed by Amgen) for osteoporosis and bone-related conditions. This approval allows the company to market the biosimilar across European Union member states. The move strengthens Dr. Reddy's biosimilars portfolio in a key regulated market.
Positive for the company as it opens a large, lucrative European market for a high-demand biosimilar, potentially driving future revenue growth in the biologics segment.